|
|
Article: Affymax and Takeda Announce Preliminary Phase 2 Data Demonstrated That Hematide[TM] Increased Hemoglobin in Dialysis Patients.
- Article from:
- Business Wire
- Article date:
- October 30, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Presentations at American Society of Nephrology Renal Week 2009 Characterize Binding, Immunogenicity Profile for Hematide
PALO ALTO, Calif. & DEERFIELD, Ill. -- Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a Phase 2 trial which demonstrated that Hematide increased hemoglobin levels in a group of anemic hemodialysis (HD) patients. This is the first reported data from an open-label, controlled comparative study of once-monthly Hematide compared to three times per week epoetin alfa (EPO). These ...